by HTLV | Aug 21, 2022 | Publications
J Neurovirol. 2022 Jul 30. doi: 10.1007/s13365-022-01088-x. Online ahead of print. ABSTRACT Up to 3.8% of human T-lymphotropic virus type-1 (HTLV-1)-infected asymptomatic carriers (AC) eventually develop HTLV-1-associated myelopathy (HAM). HAM occurs in patients with...
by HTLV | Aug 21, 2022 | Publications
Front Immunol. 2022 Jul 22;13:957535. doi: 10.3389/fimmu.2022.957535. eCollection 2022. ABSTRACT The Human T-cell Leukemia virus type 1 (HTLV-1) causes an array of pathologies, the most aggressive of which is adult T-cell leukemia (ATL), a fatal blood malignancy with...
by HTLV | Aug 21, 2022 | Publications
Microbiol Immunol. 2022 Aug 4. doi: 10.1111/1348-0421.13022. Online ahead of print. ABSTRACT Mannose binding lectin-associated serine protease 2 (MASP2) is the effector part of mannose binding lectin (MBL) that activates the complement system in an...
by HTLV | Aug 21, 2022 | Publications
Iran J Basic Med Sci. 2022 May;25(5):586-596. doi: 10.22038/IJBMS.2022.64787.14266. ABSTRACT OBJECTIVES: Human T leukemia virus type one (HTLV-1) causes two life-threatening diseases in around five percent of infected subjects, a T cell malignancy and a...
by HTLV | Aug 21, 2022 | Publications
Ethiop J Health Sci. 2022 Jul;32(4):865-868. doi: 10.4314/ejhs.v32i4.24. ABSTRACT BACKGROUND: Available data on the burden of Human T-cell lymphotropic virus type I/II infection for eastern Africa, limited to Ethiopia, Mozambique, and Rwanda, show prevalence lower...
by HTLV | Aug 21, 2022 | Publications
Rev Soc Bras Med Trop. 2022 Aug 5;55:e0111. doi: 10.1590/0037-8682-0111-2022. eCollection 2022. ABSTRACT BACKGROUND: Infection with the human T-lymphotropic virus type 1 (HTLV-1) affects an estimated 10-15 million people worldwide. However, knowledge of the impact of...
